MolDX: Decipher Biopsy Prostate Cancer Classifier Assay for Men with Intermediate Risk Disease Final LCD - Effective May 04, 2020

This Local Coverage Determination (LCD) has completed the Open Public Meeting and Contractor Advisory Committee (CAC) comment period and is now finalized under contractor numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY). Responses to comments received may be found as a link at the bottom of the final LCD.

Medicare Coverage Database (MCD) Number/Contractor Determination Number: L38149
LCD Title: MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Intermediate Risk Disease
Effective Date: May 04, 2020
Summary of LCD: Coverage Criteria regarding the Decipher Biopsy Prostate Cancer Classifier Assay for men with intermediate risk. The previous title for this LCD was MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Unfavorable Intermediate Risk

Visit the Future LCDs webpage to access this LCD.

Last Updated Mar 16, 2020